Law360, New York (November 10, 2009, 2:20 PM ET) -- A federal judge has dismissed fraud claims from a suit brought by a putative class of patients and Zurich Insurance Co. alleging that biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a valid remedy for a lung disease it is not approved to treat.
After dismissing the first amended complaint and allowing the plaintiffs to refile, Judge Marilyn Patel dismissed state-law fraud claims from the lawsuit with prejudice Friday in the U.S. District Court for the Northern District of California. The judge also cut...
Fraud Claims Cut From Actimmune Marketing MDL
To view the full article, take a free trial now.
